{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:01:01Z","timestamp":1793113261905,"version":"4.5.0"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005485","name":"American College of Cardiology Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005485","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jfma.2024.09.023","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T09:16:13Z","timestamp":1727169373000},"page":"S42-S48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"S1","title":["Blood pressure targets, medication consideration and special concerns in elderly hypertension part I: General principles and special considerations"],"prefix":"10.1016","volume":"124","author":[{"given":"Heng-Yu","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5935-413X","authenticated-orcid":false,"given":"Po-Lung","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Hsien","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2124-5213","authenticated-orcid":false,"given":"Chun-Yi","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Wen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0552-372X","authenticated-orcid":false,"given":"Tai-Shuan","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Fan","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Yu-Chih","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7180-3607","authenticated-orcid":false,"given":"Tzung-Dau","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5278-3540","authenticated-orcid":false,"given":"Hsien-Li","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Hung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8011-1007","authenticated-orcid":false,"given":"Mu-Cyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Cheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2024.09.023_bib1","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","article-title":"2013 ESH\/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of Cardiology (ESC)","volume":"31","author":"Mancia","year":"2013","journal-title":"J Hypertens"},{"key":"10.1016\/j.jfma.2024.09.023_bib2","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa0801369","article-title":"Treatment of hypertension in patients 80 years of age or older","volume":"358","author":"Beckett","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2024.09.023_bib3","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1001\/jama.2016.7050","article-title":"Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged \u226575 Years: a randomized clinical trial","volume":"315","author":"Williamson","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jfma.2024.09.023_bib4","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMoa2111437","article-title":"Trial of intensive blood-pressure control in older patients with hypertension","volume":"385","author":"Zhang","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2024.09.023_bib5","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jacc.2016.10.077","article-title":"Outcomes of intensive blood pressure lowering in older hypertensive patients","volume":"69","author":"Bavishi","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jfma.2024.09.023_bib6","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1161\/HYPERTENSIONAHA.113.02089","article-title":"Tight versus standard blood pressure control in patients with hypertension with and without cardiovascular disease","volume":"63","author":"Reboldi","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.jfma.2024.09.023_bib7","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1291\/hypres.31.2115","article-title":"Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS)","volume":"31","year":"2008","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jfma.2024.09.023_bib8","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1161\/HYPERTENSIONAHA.109.146035","article-title":"Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study","volume":"56","author":"Ogihara","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.jfma.2024.09.023_bib9","first-page":"225","article-title":"2022 guidelines of the taiwan society of Cardiology and the taiwan hypertension society for the management of hypertension","volume":"38","author":"Wang","year":"2022","journal-title":"Acta Cardiol Sin"},{"issue":"71","key":"10.1016\/j.jfma.2024.09.023_bib10","first-page":"e13","volume":"2018","author":"Whelton","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.jfma.2024.09.023_bib11","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","article-title":"The Japanese society of hypertension guidelines for the management of hypertension (JSH 2019)","volume":"42","author":"Umemura","year":"2019","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jfma.2024.09.023_bib12","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"10.1016\/j.jfma.2024.09.023_bib13","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/gerona\/glv228","article-title":"Characterizing frailty status in the systolic blood pressure intervention trial","volume":"71","author":"Pajewski","year":"2016","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.jfma.2024.09.023_bib14","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1097\/00004872-199608000-00003","article-title":"Associations of orthostatic blood pressure fall in older patients with isolated systolic hypertension. Syst-Eur Investigators","volume":"14","author":"Vanhanen","year":"1996","journal-title":"J Hypertens"},{"key":"10.1016\/j.jfma.2024.09.023_bib15","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1001\/jamainternmed.2013.14764","article-title":"Antihypertensive medications and serious fall injuries in a nationally representative sample of older adults","volume":"174","author":"Tinetti","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jfma.2024.09.023_bib16","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1001\/2013.jamainternmed.469","article-title":"The risk of hip fracture after initiating antihypertensive drugs in the elderly","volume":"172","author":"Butt","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jfma.2024.09.023_bib17","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/ajh\/hpv177","article-title":"Functional status and antihypertensive therapy in older adults: a new perspective on old data","volume":"29","author":"Charlesworth","year":"2015","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jfma.2024.09.023_bib18","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12916-015-0328-1","volume":"13","author":"Warwick","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.jfma.2024.09.023_bib19","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41371-018-0086-6","article-title":"Impact of SPRINT results on hypertension guidelines: implications for \u201cfrail\u201d elderly patients","volume":"32","author":"Russo","year":"2018","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.jfma.2024.09.023_bib20","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamainternmed.2014.8012","article-title":"Treatment with multiple blood pressure medications, achieved blood pressure, and mortality in older nursing home residents: the PARTAGE study","volume":"175","author":"Benetos","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jfma.2024.09.023_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101304","article-title":"Do the frail experience more adverse events from intensive blood pressure control? A 2-year prospective study in the Irish Longitudinal Study on Ageing (TILDA)","volume":"45","author":"O'Donoghue","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jfma.2024.09.023_bib22","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1001\/jamainternmed.2022.1657","article-title":"Time to clinical benefit of intensive blood pressure lowering in patients 60 years and older with hypertension: a secondary analysis of randomized clinical trials","volume":"182","author":"Chen","year":"2022","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jfma.2024.09.023_bib23","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1001\/jamacardio.2019.6192","article-title":"Assessment of long-term benefit of intensive blood pressure control on residual life span: secondary analysis of the Systolic Blood Pressure Intervention Trial (SPRINT)","volume":"5","author":"Vaduganathan","year":"2020","journal-title":"JAMA cardiology"},{"key":"10.1016\/j.jfma.2024.09.023_bib24","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/ehjqcco\/qcaa035","article-title":"Time to benefit and harm of intensive blood pressure treatment: insights from SPRINT","volume":"7","author":"Krishnaswami","year":"2021","journal-title":"European Heart Journal-Quality of Care and Clinical Outcomes"},{"key":"10.1016\/j.jfma.2024.09.023_bib25","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/ajh\/hpy169","article-title":"Effect modification by age on the benefit or harm of antihypertensive treatment for elderly hypertensives: a systematic review and meta-analysis","volume":"32","author":"Huang","year":"2019","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jfma.2024.09.023_bib26","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.jacc.2016.07.754","article-title":"Diastolic blood pressure, subclinical myocardial damage, and cardiac events: implications for blood pressure control","volume":"68","author":"McEvoy","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jfma.2024.09.023_bib27","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/S0140-6736(16)31326-5","article-title":"Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study","volume":"388","author":"Vidal-Petiot","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2024.09.023_bib28","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1161\/HYPERTENSIONAHA.122.20120","article-title":"Genetically predicted differences in systolic blood pressure and risk of cardiovascular and noncardiovascular diseases: a Mendelian Randomization Study in Chinese adults","volume":"80","author":"Clarke","year":"2023","journal-title":"Hypertension"},{"key":"10.1016\/j.jfma.2024.09.023_bib29","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1001\/jama.1991.03460240051027","article-title":"Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP)","volume":"265","year":"1991","journal-title":"JAMA"},{"key":"10.1016\/j.jfma.2024.09.023_bib30","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(97)05381-6","article-title":"Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators","volume":"350","author":"Staessen","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2024.09.023_bib31","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1097\/00004872-199816120-00016","article-title":"Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group","volume":"16","author":"Liu","year":"1998","journal-title":"J Hypertens"},{"key":"10.1016\/j.jfma.2024.09.023_bib32","first-page":"1175","article-title":"Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE)","volume":"44","author":"Papademetriou","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jfma.2024.09.023_bib33","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/HJH.0b013e3282f283c9","article-title":"A comparison of atenolol and nebivolol in isolated systolic hypertension","volume":"26","author":"Dhakam","year":"2008","journal-title":"J Hypertens"},{"key":"10.1016\/j.jfma.2024.09.023_bib34","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehy339","article-title":"ESC\/ESH Guidelines for the management of arterial hypertension","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"issue":"Suppl. 1","key":"10.1016\/j.jfma.2024.09.023_bib35","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.2337\/dc17-0299","article-title":"Standards of medical care in diabetes-2017","volume":"40","author":"Sonne","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jfma.2024.09.023_bib36","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"International society of hypertension global hypertension practice guidelines","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.jfma.2024.09.023_bib37","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38","volume":"317","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.jfma.2024.09.023_bib38","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1097\/HJH.0b013e328338a89c","article-title":"Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial","volume":"28","author":"Ninomiya","year":"2010","journal-title":"J Hypertens"},{"key":"10.1016\/j.jfma.2024.09.023_bib39","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1001\/jama.1996.03540230036032","article-title":"Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension","volume":"276","author":"Curb","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.jfma.2024.09.023_bib40","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"Cushman","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2024.09.023_bib41","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1161\/01.HYP.0000143851.23721.26","article-title":"Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study","volume":"44","author":"Bakris","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.jfma.2024.09.023_bib42","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1001\/jama.2020.4871","article-title":"Effect of antihypertensive medication reduction vs usual care on short-term blood pressure control in patients with hypertension aged 80 Years and older: the OPTIMISE randomized clinical trial","volume":"323","author":"Sheppard","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jfma.2024.09.023_bib43","doi-asserted-by":"crossref","first-page":"d7541","DOI":"10.1136\/bmj.d7541","article-title":"Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial","volume":"344","author":"Beckett","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jfma.2024.09.023_bib44","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/14656566.2018.1456529","article-title":"Drug treatment of hypertension in older patients with diabetes mellitus","volume":"19","author":"Yandrapalli","year":"2018","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.jfma.2024.09.023_bib45","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2165\/11316430-000000000-00000","article-title":"ACE inhibitor and angiotensin II type 1 receptor antagonist therapies in elderly patients with diabetes mellitus: are they underutilized?","volume":"27","author":"Pappoe","year":"2010","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jfma.2024.09.023_bib46","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12933-022-01545-1","article-title":"Effects of sacubitril\/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials","volume":"21","author":"Wijkman","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jfma.2024.09.023_bib47","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/HYPERTENSIONAHA.116.08484","article-title":"Effects of sacubitril\/valsartan (LCZ696) on natriuresis, diuresis, blood pressures, and NT-proBNP in salt-sensitive hypertension","volume":"69","author":"Wang","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.jfma.2024.09.023_bib48","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2024.09.023_bib49","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJM199903043400902","article-title":"Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators","volume":"340","author":"Tuomilehto","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2024.09.023_bib50","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12933-016-0485-3","article-title":"Blood pressure control in type 2 diabetic patients","volume":"16","author":"Grossman","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jfma.2024.09.023_bib51","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.amjhyper.2006.05.018","article-title":"Efficacy of indapamide SR compared with enalapril in elderly hypertensive patients with type 2 diabetes","volume":"20","author":"Puig","year":"2007","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jfma.2024.09.023_bib52","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s11906-005-0006-3","article-title":"New-onset diabetes in treated hypertensive patients","volume":"7","author":"Verdecchia","year":"2005","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.jfma.2024.09.023_bib53","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f6745","article-title":"Role of diuretics, \u03b2 blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study","volume":"347","author":"Shen","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.jfma.2024.09.023_bib54","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00002512-200320010-00002","article-title":"Beta-blockers after acute myocardial infarction in elderly patients with diabetes mellitus: time to reassess","volume":"20","author":"Di Bari","year":"2003","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jfma.2024.09.023_bib55","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/S0140-6736(68)90272-9","article-title":"Propranolol and hypoglycaemia","volume":"1","author":"Reveno","year":"1968","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2024.09.023_bib56","first-page":"291","article-title":"Effect of \u03b2-blocker therapy in diabetic patients with stable coronary heart disease: a meta-analysis","volume":"16","author":"Malik","year":"2019","journal-title":"J Geriatr Cardiol"},{"key":"10.1016\/j.jfma.2024.09.023_bib57","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/jch.14556","article-title":"Role of \u03b11-blockers in the current management of hypertension","volume":"24","author":"Li","year":"2022","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.jfma.2024.09.023_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106396","article-title":"SGLT2-inhibitors are effective and safe in the elderly: the SOLD study","volume":"183","author":"Lunati","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jfma.2024.09.023_bib59","doi-asserted-by":"crossref","first-page":"927","DOI":"10.4103\/jfmpc.jfmpc_644_21","article-title":"Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: a systematic review and quantitative analysis","volume":"11","author":"Dutta","year":"2022","journal-title":"J Fam Med Prim Care"},{"key":"10.1016\/j.jfma.2024.09.023_bib60","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1136\/pgmj.72.847.263","article-title":"The diabetic patient with hypertension","volume":"72","author":"Leese","year":"1996","journal-title":"Postgrad Med"},{"key":"10.1016\/j.jfma.2024.09.023_bib61","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJM199403313301301","article-title":"The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group","volume":"330","author":"Klahr","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2024.09.023_bib62","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jfma.2024.09.023_bib63","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1056\/NEJMoa0910975","article-title":"Intensive blood-pressure control in hypertensive chronic kidney disease","volume":"363","author":"Appel","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2024.09.023_bib64","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.jacc.2014.04.065","article-title":"Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population","volume":"64","author":"Sim","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jfma.2024.09.023_bib65","article-title":"Chronic kidney disease: summary of updated NICE guidance","volume":"374","author":"Martinez","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jfma.2024.09.023_bib66","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","article-title":"KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"99","author":"Cheung","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.jfma.2024.09.023_bib67","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.jfma.2024.09.023_bib68","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1747-4949.2010.00573.x","article-title":"The secondary prevention of Small subcortical strokes (SPS3) study","volume":"6","author":"Benavente","year":"2011","journal-title":"Int J Stroke"},{"key":"10.1016\/j.jfma.2024.09.023_bib69","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2024.09.023_bib70","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2024.09.023_bib71","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1681\/ASN.2017020148","article-title":"Effects of intensive BP control in CKD","volume":"28","author":"Cheung","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2024.09.023_bib72","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1681\/ASN.2006121372","article-title":"Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency","volume":"18","author":"Hou","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2024.09.023_bib73","doi-asserted-by":"crossref","first-page":"c63","DOI":"10.1159\/000228536","article-title":"Analytical review of the evidence for renoprotection by renin-angiotensin-aldosterone system blockade in chronic kidney disease - a call for caution","volume":"113","author":"Onuigbo","year":"2009","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.jfma.2024.09.023_bib74","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2024.09.023_bib75","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahl\u00f6f","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2024.09.023_bib76","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2024.09.023_bib77","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jfma.2024.09.023_bib78","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.amjcard.2004.08.059","article-title":"Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes","volume":"95","author":"Kostis","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jfma.2024.09.023_bib79","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","article-title":"Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients","volume":"359","author":"Jamerson","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2024.09.023_bib80","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.amjmed.2010.02.014","article-title":"Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy","volume":"123","author":"Denardo","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.jfma.2024.09.023_bib81","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664624004431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664624004431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T08:32:19Z","timestamp":1762331539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664624004431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":81,"alternative-id":["S0929664624004431"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2024.09.023","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blood pressure targets, medication consideration and special concerns in elderly hypertension part I: General principles and special considerations","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2024.09.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2025, Formosan Medical Association. Published by Elsevier Taiwan LLC. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}